Measuring prevalence of high risk medicines use in community pharmacies
Safe dispensing indicators:
Indicator | Description of conditions |
---|---|
1. Warfarin and INR monitoring |
1. Number of patients dispensed a prescription for warfarin AND 2. Whose latest INR result is not recorded in the pharmacy’s Patient Medication Record (PMR) system |
2. Dosing instructions for methotrexate |
1. Number of patients dispensed a prescription for methotrexate AND 2. The prescription contains no or non-specific directions for use (e.g. “to be taken as directed”) |
3. Verapamil in combination with beta-blockers |
1. Number of patients dispensed a prescription for verapamil AND 2. Who are also dispensed a prescription for a beta-blocker |
4. Use of valproate in girls and women of childbearing potential (1) |
1. Number of patients dispensed a prescription for sodium valproate or valproic acid AND 2. Who are female AND 3. Who are aged between 13 and 45 |
5. Use of valproate in girls and women of childbearing potential (2) |
Of the patients identified in number 4, the number who have been provided the patient information booklet. |
6. Over 65s prescribed an antipsychotic medicine |
1. Numbers of patients dispensed prescriptions for antipsychotic medicine AND 2. Where the patient is aged 65 or over |
7. Warfarin and oral NSAIDs |
1. Number of patients dispensed a prescription for warfarin AND 2. Who are also dispensed a prescription for an oral Non-Steroidal Anti-Inflammatory Drug (NSAID) |
8. NSAIDs in combination with aspirin or clopidogrel without gastroprotection |
1. Number of patients dispensed a prescription for an NSAID AND 2. Who are dispensed a prescription for aspirin or clopidogrel AND 3. Who are not dispensed a prescription for suitable gastroprotection (PPI or H2 antagonist) AND 4. Are aged 65 or over |
9. Excessive use of short acting bronchodilators in asthma |
1. Number of patients who have been dispensed prescriptions or received emergency supplies (combined total) of more than 6 inhaled short acting beta agonists in the previous 6 months AND 2. Who have not been prescribed an inhaled corticosteroid in the previous 6 months |
Submission date |
Period to which data relates |
Indicators |
Between 1 and 31 May 2019 |
April 2019 |
1 to 5 |
Between 1 and 31 August 2019 |
July 2019 |
6 to 9 |
Between 1 and 30 November 2019 |
October 2019 |
1 to 5 |
Between 1 February and 28 February 2020 |
January 2020 |
6 to 9 |
Data will be submitted through NECAF and the data submission screen will be open only for the dates shown.
http://www.cpwales.org.uk/Services-and-commissioning/Quality-Scheme/High-Risk-Medicines-Survey.aspx